The Internet belongs to everyone. Let’s keep it that way.

Protect Net Neutrality
Loading presentation...

Present Remotely

Send the link below via email or IM


Present to your audience

Start remote presentation

  • Invited audience members will follow you as you navigate and present
  • People invited to a presentation do not need a Prezi account
  • This link expires 10 minutes after you close the presentation
  • A maximum of 30 users can follow your presentation
  • Learn more about this feature in our knowledge base article

Do you really want to delete this prezi?

Neither you, nor the coeditors you shared it with will be able to recover it again.


Copy of Twenty Years of Advancing Public Health Solutions

No description

Nicole Cavino

on 19 May 2014

Comments (0)

Please log in to add your comment.

Report abuse

Transcript of Copy of Twenty Years of Advancing Public Health Solutions

Twenty Years of Advancing Public Health Solutions
Ciro de Quadros, MD, MPH
Executive Vice President
Sabin Vaccine Institute
April 25, 2014

70-80% of global birth cohort was covered by basic immunization
1993: A Snapshot
100,000+ cases of poliomielitis
per year
1.2 million cases of measles
per year
Few national immunization plans
outside of the Americas
No vaccines
for rotavirus,
pneumococcal, or HPV
Neglected tropical diseases (NTDs) were unrecognized
as a group of diseases
No vaccines
in development for
these diseases
Organizations, like the Bill & Melinda Gates Foundation, GAVI, the Sabin Vaccine Institute and others focused on controlling, eliminating and eradicating these diseases
did not exist
Sabin Vaccine Institute
Cancer Vaccine Consortium

Cold Spring Harbor Laboratory
Human Hookworm Vaccine Initiative
Vaccine Advocacy & Education
The Global Network for Neglected
Tropical Diseases
Sabin PDP
Sabin Foundation Europe
Education and Knowledge Sharing
Partnerships: CaT
Innovative Public Health Solutions:
Sabin PDP
What we are doing:
developing effective,
low-cost vaccines

that will benefit under-served populations

: a new blueprint for vaccine development and efforts to fight public health threats for the world's poor

Our Portfolio

Phase 1 testing in Brazil, Phase 1 testing in U.S., Phase 1 testing to begin in sub-Saharan Africa (2014)
IND Submission (Fall 2013), Phase 1 testing in U.S. (Q4 2013) and in Brazil (Q1 2014)
Leishmaniasis and Chagas

Preclinical; candidates selected; process development and scale up ongoing
Integration and Efficiency:
Global Network
What we are doing:
Building a movement to prioritize funding and political support for global NTD programs

How we are doing it:
dvocating policy and funding solutions, building partnerships across health sectors and developing innovative communications practices to generate greater media coverage, public support and policy engagement on NTD-related issues

74 countries
now have national NTD plans
Strengthening regional institutions
Addition of policy champions and celebrity supporters
$164 million of new resources for NTD programs and leveraged approximately $1.4 billion in indirect benefits to affected populations
Elevating NTDs as a mainstream health issue to policymakers, leading media outlets and the general public through our END7 campaign and direct policy engagement
Country Ownership and Sustainability:
Sustainable Immunization Financing
What we are doing:

Working with
22 countries
to make sound
budget decisions
allocate resources
; establish
Parliamentary oversigh
t and
raise public demand
for immunizations; and engage
external partnerships

How we are doing it:

Holding 100+ advocacy events per year
Fostering peer-to-peer exchanges
Improving inter-agency communications within national governments, particularly between health and finance ministries

What's next for Sabin?
Bringing together key stakeholders and leaders in government, private sector, academia and civil society in order to foster cooperation, share information and best practices, and develop
improved vaccine policy, financing and access
Developing and introducing
new vaccines
for infectious and neglected diseases
Building political support, funding and public awareness required to prioritize NTDs as a global health threat and to
grow a movement

dedicated to their control
What we are doing:
Educate leaders from national governments, the private sector, media and civil society organizations on the value of immunizations and encourage collaboration among all development partners each year


24 International symposia, more than 4,200 participants
2 Journalist trainings, almost 100 participants
3 Vaccinology courses, nearly 150 trained

How we are doing it:

was launched in 2013 to create the first global professional network for immunization managers
Improve technical and leadership capacity
Hold conferences and web-sessions to share best practices
Produce materials and foster peer exchanges
What we are doing:

to expedite and sustain rational, evidence-based decision-making around the use of typhoid vaccines and to define barriers to the adoption of typhoid vaccines in communities that would benefit most

WHO ECBS issued guidelines to assist national regulatory authorities in assessing the quality, safety and efficacy of typhoid conjugate vaccines

The issuance of these guidelines is a critical step in achieving the long-term goal of a WHO pre-qualified typhoid vaccine.
We are expanding and deepening our activities to
reduce needless human suffering
from vaccine-preventable and neglected tropical diseases (NTDs) by:

Expanding capacity-building vaccine advocacy and education initiatives

Introducing new vaccine candidates for diseases of poverty and forging new strategic partnerships to support development pipelines

Deepening advocacy with development partners and middle-income endemic countries to increase government funding for NTD programs.

How will we do it?
Two road maps exist to guide us to close the major gaps that still exist for the control and elimination of NTDs and vaccine-preventable diseases :

2012 London Declaration on NTDs

The Global Vaccine Action Plan (GVAP) unanimously approved by the WHA in May 2012

Full transcript